We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Gen Products Driving Global POC Molecular Diagnostics Market

By LabMedica International staff writers
Posted on 31 Dec 2018
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.

These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

The growing number of M&As and collaborations is acting as a key growth driver of the global POC molecular diagnostics market. More...
Large companies have been increasingly acquiring and collaborating with specialized POC molecular diagnostic companies to expand their product portfolio. As a result, the parent companies have reduced their internal costs for product development, clinical study, and regulatory approvals.

The growing emphasis on technological advances will accelerate the growth of the global POC molecular diagnostics market. Advances in the field of information technology are providing ease of transmission by electronically recording and transferring the data captured. The shift from curative medicine to predictive, personalized, and preemptive medicine is also driving an increasing demand for POC molecular diagnostics. This shift, coupled with advances in the field of biosensors, smartphones, wearables, and lab-on-a-chip, is expected to improve the market. For instance, the lab-on-a-chip diagnostics system is formed based on the disposable, single-use, credit card sized, plastic cassette that hosts a microfluidic network for sample processing and analysis. Hence, several companies are adopting this advancement to broaden their product and service portfolios.

Based on application, the infectious diseases segment held the largest market share of more than 45% in 2018 and is expected to continue dominating the market during the forecast period. Geographically, the Americas led the global POC molecular diagnostics market in 2018 with a share of around 56%, followed by the EMEA and APAC. The Americas is expected to continue dominating the market during the forecast period.

Related Links:
Technavio Research


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.